Positive Phase II for Vanda Sleep Drug
Posted on: Monday, 26 June 2006, 09:00 CDT
In a phase II study, Vanda Pharmaceuticals' investigational insomnia medication VEC-162, a novel melatonin agonist, improved key sleep measures in adults with transient insomnia.
A randomized, double-blind study of 37 healthy subjects was conducted to evaluate the efficacy of VEC-162 (10, 20, 50 and 100mg) in a model of transient insomnia. The primary objectives of the study were to evaluate the efficacy of VEC-162 in shifting patients' circadian rhythm as measured by plasma melatonin and in improving time to persistent sleep as measured by polysomnography (PSG) when compared with placebo in a model of transient insomnia. Secondary objectives included wakefulness after sleep onset (WASO), safety and tolerability.
On circadian rhythm, there was a statistically significant shift in circadian rhythm at 50 and 100mg of up to five hours in the first night, and a statistically significant dose-response curve. On polysomnographic measures of sleep efficacy, all dosing arms experienced a reduction in time it took to achieve persistent sleep.
"We are encouraged by these clinical results which demonstrate that, in VEC-162, we may have the first therapy available to treat the millions of patients who suffer from the consequences of a misalignment of their sleep/wake cycle," said Dr Mihael Polymeropoulos, CEO of Vanda.
The data were presented at the SLEEP 20th anniversary meeting of the Associated Professional Sleep Societies (APSS) by Dr Shantha Rajaratnam, of the division of sleep medicine at Brigham and Women's Hospital, Harvard Medical School.
Source: Datamonitor
Related Articles
- Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
- Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
- ImmunoCellular Therapeutics Announces Completion of Proof-of-Principle Studies Demonstrating Efficacy of Cancer Stem Cell Vaccine in Preclinical Model
- Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
- 1-2-3 Study Demonstrates Efficacy of NovoLog(R) Mix 70/30 in Reaching American Diabetes Association A1C Targets With Once-Daily Dosing and the Additional Benefit of Intensifying Therapy
- Two Studies Support Efficacy of Critical Therapeutics' ZYFLO in Moderate to Severe Asthma Patients; Data Presented at the American Thoracic Society's 2005 International Conference
- New Study Showed Efficacy Was Most Important Factor in Decision to Stay on Antipsychotic Treatment for Schizophrenia
- Predictors of Heartburn During Sleep in a Large Prospective Cohort Study*
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Adults With Primary Sleep Maintenance Insomnia
 |
 |
User Comments (0)
RSS Feeds